Brian I. Rini

Generating author description...

All published works

Action	Title	Year	Authors
+	Data from Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma	2024	Toni K. Choueiri Amber C. Donahue David A. Braun Brian I. Rini Thomas Powles John B.A.G. Haanen James Larkin Xinmeng Jasmine Mu Jie Pu Rosemary E. Teresi
+	Data from Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma	2024	Toni K. Choueiri Amber C. Donahue David A. Braun Brian I. Rini Thomas Powles John B.A.G. Haanen James Larkin Xinmeng Jasmine Mu Jie Pu Rosemary E. Teresi
+	Supplementary Figures S1-S6 from Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma	2024	Toni K. Choueiri Amber C. Donahue David A. Braun Brian I. Rini Thomas Powles John B.A.G. Haanen James Larkin Xinmeng Jasmine Mu Jie Pu Rosemary E. Teresi
+	Supplementary Figures S1-S6 from Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma	2024	Toni K. Choueiri Amber C. Donahue David A. Braun Brian I. Rini Thomas Powles John B.A.G. Haanen James Larkin Xinmeng Jasmine Mu Jie Pu Rosemary E. Teresi
+ PDF Chat	Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma	2023	Toni K. Choueiri Amber C. Donahue David A. Braun Brian I. Rini Thomas Powles John B.A.G. Haanen James Larkin Xinmeng Jasmine Mu Jie Pu Rosemary E. Teresi
+	Supplementary Figure 3 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer	2023	Soledad Negrotto Zhenbo Hu Óscar Garnica Kwok Peng Ng Pierre L. Triozzi Daniel J. Lindner Brian I. Rini Yogen Saunthararajah
+	Supplementary Figure 2 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer	2023	Soledad Negrotto Zhenbo Hu Óscar Garnica Kwok Peng Ng Pierre L. Triozzi Daniel J. Lindner Brian I. Rini Yogen Saunthararajah
+	Supplementary Figure 2 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer	2023	Soledad Negrotto Zhenbo Hu Óscar Garnica Kwok Peng Ng Pierre L. Triozzi Daniel J. Lindner Brian I. Rini Yogen Saunthararajah
+	Supplementary Figure 3 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer	2023	Soledad Negrotto Zhenbo Hu Óscar Garnica Kwok Peng Ng Pierre L. Triozzi Daniel J. Lindner Brian I. Rini Yogen Saunthararajah
+	Data from Noncytotoxic Differentiation Treatment of Renal Cell Cancer	2023	Soledad Negrotto Zhenbo Hu Óscar Garnica Kwok Peng Ng Pierre L. Triozzi Daniel J. Lindner Brian I. Rini Yogen Saunthararajah
+	Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years	2018	Pedro Barata Brian P. Hobbs Brian I. Rini Channing J. Paller Daniel P. Normolle Elizabeth Garrett‐Mayer Eric H. Rubin Gary L. Rosner Gregory R. Pond Jane Perlmutter
+ PDF Chat	Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?	2015	Susan Halabi Brian I. Rini Bernard Escudier Walter M. Stadler Eric J. Small

Common Coauthors

Coauthor	Papers Together
Jie Pu	5
Yogen Saunthararajah	5
Toni K. Choueiri	5
Daniel J. Lindner	5
Zhenbo Hu	5
Robert J. Motzer	5
Alessandra di Pietro	5
Paul B. Robbins	5
Xinmeng Jasmine Mu	5
David A. Braun	5
John B.A.G. Haanen	5
Soledad Negrotto	5
Amber C. Donahue	5
James Larkin	5
Pierre L. Triozzi	5
Rosemary E. Teresi	5
Óscar Garnica	5
Thomas Powles	5
Kwok Peng Ng	5
Walter M. Stadler	1
Tatiana M. Prowell	1
Brian P. Hobbs	1
Percy Ivy	1
Nolan A. Wages	1
Eric J. Small	1
Gary L. Rosner	1
David S. Hong	1
Elizabeth Garrett‐Mayer	1
Lesley Seymour	1
Gregory R. Pond	1
Lillian L. Siu	1
Bernard Escudier	1
Susan Halabi	1
Daniel P. Normolle	1
Pedro Barata	1
Timothy A. Yap	1
Jane Perlmutter	1
Eric H. Rubin	1
Channing J. Paller	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?	2013	Andreas Becker Christian Eichelberg Maxine Sun	1
+	Criteria for the Validation of Surrogate Endpoints in Randomized Experiments	1998	Marc Buyse Geert Molenberghs	1
+ PDF Chat	Predicting Treatment Effect from Surrogate Endpoints and Historical Trials: An Extrapolation Involving Probabilities of a Binary Outcome or Survival to a Specific Time	2011	Stuart G. Baker Daniel J. Sargent Marc Buyse Tomasz Burzykowski	1
+ PDF Chat	Measurement of Diversity	1949	Edward Simpson	1
+ PDF Chat	Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points	2001	Tomasz Burzykowski Geert Molenberghs Marc Buyse Helena Geys Didier Renard	1
+ PDF Chat	The validation of surrogate endpoints in meta-analyses of randomized experiments	2000	Marc Buyse Geert Molenberghs Tomasz Burzykowski Didier Renard Helena Geys	1
+	Statistical validation of intermediate endpoints for chronic diseases	1992	Laurence S. Freedman Barry I. Graubard Arthur Schatzkin	1
+	Surrogate endpoints in clinical trials: Definition and operational criteria	1989	Ross L. Prentice	1
+ PDF Chat	On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm	2008	Debashis Ghosh	1
+ PDF Chat	The ASA Statement on <i>p</i>-Values: Context, Process, and Purpose	2016	Ronald L. Wasserstein Nicole A. Lazar	1
+	A Confidence Interval for the Median Survival Time	1982	Ron Brookmeyer John Crowley	1
+ PDF Chat	The <i>p</i>-Value Requires Context, Not a Threshold	2019	Rebecca A. Betensky	1